NIH’s All of Us program launches BYOD project: Another use case for future trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pressureUA)
(Image: Getty/pressureUA)

Related tags: Thread, Nih, Precision medicine, Wearables, mHealth, Pharmacogenomics, BYOD, Digital

The All of Us research program is expanding its data collection abilities via Fitbit – a move that further demonstrates the industry’s increasing adoption of a BYOD approach, says Thread executive.

The National Institutes of Health’s (NIH) program, part of the Precision Medicine Initiative (PMI) which launched in 2016​, aims to enroll more than one million US participants by 2020.

The study is not focusing on a specific disease. Instead, researchers hope to create a platform to enable trials of targeted therapies and to gain a better understanding of the use of mobile health (mHealth), among other goals.

Read: Million-person precision medicine study 'a constant learning process'

In line with this, the All of Us research program this week launched​ the Fitbit bring-your-own-device (BYOD) project – a “key step”​ in the program’s goal to integrate digital technology.

Participants now will be able to share data from their Fitbit accounts, in addition to providing information through surveys, electronic health records (EHRs), and biosamples.

NIH is planning to further incorporate digital health technologies in the program with a second Fitbit project slated to launch later this year. This will include providing devices to a select number of All of Us participants who will be randomly invited to participate.

According to the NIH, the program will add connections to additional devices and applications in the future.

Continuing BYOD momentum

John Reites, chief product officer and partner at Thread​, said the announcement is yet another example of the continued momentum toward standard use of BYOD mobile and wearables for research.

We are not only seeing this approach used in post-approval research and registries but also Phase II/III studies,”​ he told us, noting the several advantages to a BYOD approach, including increased insights with built-in patient engagement at lower costs.

“The challenges our industry is still working through for broader adoption of a BYOD wearable approach is that not everyone owns a wearable device, not everyone will opt-in/consent to donate their data and the outcomes gathered will likely support exploratory endpoints at first,” ​Reites explained.

However, today’s studies using this approach will help address these challenges, defining additional use cases for the future, ​he said.

“It’s great to see the All of Us Research Program and Fitbit team moving this innovative approach forward,”​ Reites added. “Examples like this study are enabling life science organizations to strongly consider BYOD wearable approaches for their studies.”

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more